Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Opinion

Respiratory mucus as a virus-host range determinant

Louisa E. Wallace,1,2 Mengying Liu,1,2 Frank J.M. van Kuppeveld,1 Erik de Vries,1,* and Cornelis A.M. de Haan1,*

Efficient penetration of the mucus layer is needed for respiratory viruses to avoid mucociliary clearance prior to infection. Many respiratory viruses bind to glycans on the heavily glycosylated mucins that give mucus its gel-like characteristics. Influenza viruses, some paramyxoviruses, and coronaviruses avoid becoming trapped in the mucus by releasing themselves by means of their envelope-embedded enzymes that destroy glycan receptors. For efficient infection, receptor binding and destruction need to be in balance with the host receptor repertoire. Establishment in a novel host species requires resetting of the balance to adapt to the different glycan repertoire encountered. Growing understanding of species-specific mucosal glycosylation patterns and the dynamic interaction with respiratory viruses identifies the mucus layer as a major host-range determinant and barrier for zoonotic transfer.

Respiratory mucus and viruses

All body surfaces exposed to the outside world are protected against environmental hazards by a layer of closely connected epithelial cells. The multiple layers of dead cells of the skin can be passed by viruses only via animal bites, wounds or needles. However, 95% of epithelial surfaces are mucosal surfaces consisting of a single layer of epithelial cells mostly covered by a gel-like layer of mucus (see Glossary). They form semipermeable barriers enabling nutrient absorption and waste secretion and provide a major route of entry and release for pathogens, including viruses. The mucus layer contains a range of mucin glycoproteins as the main components; they are secreted by specialized secretory epithelial cells. Mucus provides protection against dehydration, abrasion, toxins, and pathogens, and is a reservoir for antimicrobial molecules [1]. In the respiratory tract, heavily glycosylated and sialylated mucins form a barrier against glycan-receptor-binding viruses, which are at risk of being expelled by mucociliary clearance (MCC) after immobilization in the mucus layer [2]. This is counteracted by respiratory viruses – such as influenza viruses, some coronaviruses, and paramyxoviruses – which release themselves from decoy receptors by the action of their associated glycan-receptor-destroying enzymes (RDEs) [3].

Host species differ in the genetic makeup and expression of their glycan-modifying enzymes, resulting in a species-specific sialoglycan repertoire on functional cell surface receptors as well as soluble decoy receptors in the mucus [4–6]. Glycan-binding viruses usually have a restricted host range invoked by optimal adaptation to the glycan repertoire of a specific host species amongst other factors. Host-specific evolution – leading to well-balanced binding to, and cleavage from, epithelial cell surface receptors – has been extensively documented for influenza viruses [7–9] and others [10,11]. However, such a balance is also required to prevent immobilization on mucus decoy receptors leading to virus expulsion before reaching the epithelial cells. Thus, animal viruses that have successfully crossed the host species barrier to become human viruses, will not only have adjusted the specificity and/or affinity of their glycan-receptor...
binding proteins (RBPs) and RDEs to match the sialoglycan repertoire of the epithelial cells but also to the rather different glycan repertoire of the mucus layer. The mucus layer can therefore be regarded as a major host-range determinant. In this opinion paper, we discuss our current understanding of the zoonotic barrier function of the mucus layer for glycan-binding respiratory viruses and indicate the major gaps in our knowledge. Table 1 summarizes the properties of respiratory viruses that bind to glycans, including all viruses that are discussed in more detail below.

The respiratory mucus layer and its protein constituents

Respiratory mucus, or airway surface liquid (ASL) is comprised of two distinct layers – the viscous gel-like mucus layer that is situated on top of the periciliary layer (PCL) – described by a ‘gel-on-brush’ model [12] (Figure 1). Mucins form the main constituents of both layers. They are large macromolecules (200–1500 kDa in their monomeric state) that assemble into networks of up to 200 MDa in size [2] that are conserved throughout the vertebrate kingdom. The protein backbone of mucins contains unique tandem repeats rich in proline, threonine, and serine – referred to as PTS domains – which are extensively modified with a heterogeneous array of O-glycans contributing to 50–80% of their molecular weight. Twenty-two mucins have been identified in humans, 16 of which have been found in the respiratory tract.

The superficial gel layer (~2–10 μm) consists mainly of the large (~5800 amino acids) gel-forming mucins MUC5AC and MUC5B that are secreted from goblet cells and mucous cells of the submucosal glands, respectively (Figure 1). They multimerize into extended polymers (0.5–10 μm) by disulfide bonds between the N- and C-terminal cysteine-rich von Willebrand factor (vWF) domains (Figures 1 and 2), and along with mucin-interacting globular proteins form a dynamic, porous molecular network with pores ranging from 100 to 500 nm that impede the penetration of invading pathogens through the layer to the airway epithelia, thus facilitating removal by mucociliary clearance [13]. The underlying PCL is as deep as cilia are in height (~7 μm) and is reduced in viscosity, providing a favorable environment for ciliary beating and cell surface lubrication. Membrane-spanning mucins (MUC1, MUC4, MUC16, and MUC20) and mucopolysaccharides present on cilia and airway epithelium form a meshwork that increases in density closer to the epithelial surface, enabling the exclusion of molecules and nanoparticles through this ASL layer [12]. Mucus covers the length of the respiratory tract, excluding the alveoli, with a thicker layer present in the upper respiratory tract that decreases moving down to the bronchi and bronchioles of the lower respiratory tract [14]. The mucus layer can vary in composition and properties due to changes in physiology and health, including virus and bacterial infections, which may affect its barrier function.

Although mucins serve as the major functional and structural component of mucus, respiratory epithelial cells secrete a myriad of nonmucin proteins, including enzymes, antimicrobial peptides, protease inhibitors and oxidants which accumulate and play important functional roles in the mucus layer [15]. Many of these mucus constituents have been identified from human bronchoalveolar lavage fluid, fluid from primary human airway epithelial cultures, fluid from the serous glands of the Calu-3 cell line, and nasal lavage fluid using proteomics mass spectrometry, chromatography, 2D PAGE and ELISA approaches [16,17]. Several of these proteins have been found to have antiviral effects – such as human defensin-β [18], lactoferrin [19], palatine lung and nasal epithelium clone (PLUNC) [20], cathelicidins (specifically LL-37) [21], pulmonary surfactant proteins A and D [22], deleted in malignant brain tumors 1 (DMBT1) [23], and galectins [24] – although their ability to inhibit viruses when present at physiological levels within the mucus layer in vivo is unclear. In addition, mucus appears rich in exosomes, which may also interfere with virus infection of the epithelial cells [25,26]. Studies on the protein constituents of mucus of other animal species are limited but available data suggest a similar composition as found in human mucus [16,17,27–29]. It is not clear whether putative differences between species in
protein composition and/or antiviral activities of proteins are important for the mucus layer functioning as a host tropism barrier.

**Penetration of mucus by nanoparticles**

Permeability for nanoparticles and viruses is restricted by various means, including size exclusion, hydrogen bonding, electrostatic and hydrophobic interactions, and more specific binding interactions with (sialylated) glycans [30]. For virus particles that do not utilize glycans as receptors, the ability to penetrate mucus is probably governed by physicochemical properties of mucus such as pore size, viscoelasticity, pH, ionic strength, and charge. The mesh size of respiratory mucus is highly heterogeneous (~100–500 nm); thus, for virus particles larger than the pore size, mucus acts as a biological sieve, impeding the movement of particles regardless of surface chemistry [13]. In the PCL, glycans present on cilia create an even denser network than the overlying gel layer. Particles greater than 40 nm cannot enter the PCL [12]. Smaller particles penetrate deeper with decreasing particle size, indicating an increase in glycan density closer to the cell surface. Particles with a neutral charge have much greater mobility through the mucus layer compared to charged nanoparticles. A decrease in surface charge by PEGylation resulted in an 11-fold increase in mobility rate of the nonglycan-binding porcine respiratory virus [31]. While it seems clear that the mucus layer forms a formidable barrier against penetration of virus particles [13], the physicochemical properties of mucus per se may not form a host species-specific barrier.

**Species-specific differences in respiratory mucus glycosylation**

Species-specific differences in the sialoglycan repertoire probably contribute to mucus being a host-range determinant. The glycan repertoire of the respiratory tract mucus gel layer is present on secretory gel-forming mucins MUC5AC and MUC5B, secretory non-gel-forming mucins (MUC7, MUC8, MUC19), numerous globular proteins within the MUC5AC/5B meshwork, and secreted vesicles.

The serine and threonine residues within the repeated PTS domains of mucins, including the gel-forming MUC5AC and MUC5B, are extensively modified by a highly heterogeneous collection of O-glycans that contribute over 50% to the molecular weight (Figure 2). Also, N-linked glycosylation sites are predicted in the N- and C-terminal domains of MUC5AC (17 sites) and MUC5B (32 sites) but, only for MUC5B, at least 10 N-glycans were shown to be present [32]. Mucin glycosylation patterns are determined by cell type, tissue and species-dependent expression patterns of glycosyl transferases in the goblet cells and submucosal glands from which MUC5AC and MUC5B are secreted, respectively. The large array of globular proteins and vesicles present in mucus are derived from the many cell types in the respiratory epithelial layer, cells of the immune system present in the respiratory lumen or from cell leakages in the underlying tissue and vasculature. Their glycosylation pattern, as for mucins, depends on cell origin and is expected to be highly complex and variable between species [33–37] or disease state [2,38,39] and to a large extent representing the glycome as determined for respiratory epithelium of several species. In contrast to mucins, a large amount of N-linked glycans is expected to be present.

Variations in glycan distribution in the respiratory tract between species and different locations/tissues/cells within a host have been revealed by lectin staining [40] but this technique is, at most, semiquantitative and misses a lot of detail on glycan structure. Glycan structures have been quantitatively determined by mass spectrometry glycomics analysis for several species, mostly for N-glycans. Species-specific modifications (Table 2) likely contribute to the potential of respiratory mucus as a host tropism barrier. Most of these modifications were present on glycoproteins from epithelial tissues, and their presence on glycoproteins within the mucus layer is inferred, but has not yet been convincingly demonstrated. Comprehensive studies describing the glycan composition of mucus are limited and mostly confined to humans. The
| Family     | Genus   | Sub-genus | Virus | Diameter (nm) | Receptor | RBP | RDE | Host species | Zoonotic (Z) | Enzootic (E) | Refs |
|------------|---------|-----------|-------|---------------|----------|-----|-----|--------------|--------------|--------------|------|
| Naked      | Parvo   | Dependoparvo | AAV1  | 25           | 2,3/2,6 SIA | Capsid | No   | Human        |              |              | [64] |
|            |         |           | AAV6  | 25           | 2,3/2,6 SIA | Capsid | No   | Human        |              |              | [64] |
|            |         |           | AAV5  | 25           | 2,3 SIA    | N-linked| Capsid | No   | Human        |              |              | [65] |
|            |         |           | AAV4  | 25           | 2,6 SIA    | O-linked| Capsid | No   | Human        |              |              | [65] |
| Picorna    | Entero  | EV-D68    | 30    | 2,3/2,6 SIA  | Capsid    | No   | Human |              |              |              | [66] |
| Adeno      | Mastadeno | BAd3     | 90–100| 2,3/2,6 SIA  | Capsid    | No   | Bovine|              |              |              | [67] |
| Calici     | Vesi    | FCV       | 40    | 2,6 SIA      | Capsid    | No   | Feline|              |              |              | [68] |
| Paramyxo   | Orthorubula | HPIV2/HPIV4 | 150–250 | 2,3 SIA     | HN       | HN   | Human |              |              |              | [67] |
|            | Orthoavula | NDV      | 150–400| 2,3 > 2,6 SIA| HN       | HN   | Avian |              |              |              | [69] |
|            | Respi   | HPIV1     |       | 2,3 SIA     | HN       | HN   | Human |              |              |              | [67] |
|            |         | HPIV3     |       | 2,3 > 2,6 SIA| HN       | HN   | Human |              |              |              | [70] |
|            |         | BPV-3     |       | 2,3 SIA     | HN       | HN   | Bovine| E             |              |              | [67] |
|            |         | PRV-1     |       | N.D.        | HN       | HN   | Porcine|              |              |              |      |
|            |         | CPV-3     |       | N.D.        | HN       | HN   | Caprine|              |              |              |      |
|            |         | Sendai    |       | 2,3/2,8 SIA | HN       | HN   | Murine|              |              |              | [67] |
| Corona     | Embeco  | HCoV-HKU1 | 80–120| 9-OAc SIA   | Spike HE | HE   | Human | Z             |              |              | [71] |
| Beta       |         | HCoV-OC43 |       | 9-OAc SIA   | Spike HE | HE   | Human | Z             |              |              | [71] |
|            |         | BCov      |       | 9-OAc/7, 9-di-OAc SIA | Spike HE | HE   | Bovine|              |              |              | [71] |
|            |         | PHEV      |       | 9-OAc SIA   | Spike HE | HE   | Porcine|              |              |              | [71] |
| Sarbeco    |         | SARS-CoV-2| 2,3/2,6 SIA | Spike     | No       | Human | Z             |              |              | [72] |
| Merbeco    |         | MERS-CoV  | 2,3 SIA > 2,6 SIA | Spike | No | Human | Z             |              |              | [73] |
| Gamma      | IBrV    | 2,3/2,6 SIA | Spike | No | Avian |              |              |              |              | [74] |
| Orthomyxo  | Alphainfluenza | IAV | 2,3/2,6 SIA | HA | NA | Human Avian Porcine Canine Equine Otarine | Z/E | [67] |
| Betainfluenza | IBV | 2,6 SIA > 2,3 SIA | HA | NA | Human |              |              |              |              | [67] |
| Gammainfluenza | ICV | 4-OAc/9-OAc SIA | HEF | HEF | Human Porcine Canine | Z/E | [67] |
| Deltafluenza | IDV | 4-OAc/9-OAc SIA | HEF | HEF | Bovine Caprine | E | [67] |
potential complexity of O-linked glycans is extensive [41], and over 250 different O-linked glycans have been detected on mucins purified from human respiratory mucus [39]. About half of the total O-linked glycans were sialylated and/or sulfated. The masses of sialylated O-glycans corresponded to (extended) core 1 to core 4 structures (Figure 2B) [39]. Sialic acid (SIA) linkage type, number of LacNAc repeats, sulfation, fucosylation and other modifications of terminal and subterminal residues are known to affect binding and/or cleavage by respiratory viruses. These terminal glycotopes vary between species and tissues [35] and thereby affect the relative abundance and local density of each other (Table 2). Table 2 displays typical terminal structures identified on O- and N-linked glycans from mucus and respiratory tissues. SIA linkage type (α2,3 or α2,6) is the hallmark structural element governing binding affinity of influenza A viruses (α2,3SIA binding by avian viruses; α2,6SIA binding by human and swine viruses). Whereas mucus is assumed to be abundant in α2,3SIAs because of its high content of α2,3SIA-rich O-linked glycans [35,38], a detailed quantification of the α2,3/α2,6SIA ratio including the contribution of N-linked glycans is lacking. Sulfation of O-linked glycans (especially GlcNAc-6-Sul, Gal-6-Sul, and Gal-3-Sul) on human mucins accounts for more than 50% of charged glycans, being even more abundant than sialylation [39]. Sulfation has been shown

Notes to Table 1:

Abbreviations: AAV, adeno-associated virus; EV, enterovirus; BAd3, bovine adenovirus 3; FCV, feline calicivirus; HPV, human parainfluenzavirus; MuV, mumps virus; NDV, Newcastle disease virus; B/P/CPIV3, bovine/porcine/caprine parainfluenzavirus 3; H/BCoV, human/bovine coronavirus; PHeV, porcine hemagglutinating encephalomyelitis virus; IBV, infectious bronchitis virus; IAV/IBV/ICV/IDV, influenza A/B/C/D virus. This table is not a complete list of respiratory viruses binding to sialoglycans. For more glycan-binding viruses, see https://sugarbind.expasy.org.

Abbreviations: SIA, sialic acid; 2,3 SIA, α2,3-linked SIA; 2,6 SIA, α2,6-linked SIA; 2,8 SIA, α2,8-linked SIA; N-linked and O-linked refers to SIAs attached to N-linked or O-linked glycan chains; N.D., not determined; 9-OAc SIA, 9-O-acetylated SIA; 7,9-di-O-acetylated SIA, 7,9-di-O-acetylated SIA; 4-OAc SIA, 4-O-acetylated SIA.

Abbreviations: RBP, receptor-binding protein; RDE, receptor-destroying enzyme; HN, hemagglutinin-neuraminidase; HE, hemagglutinin-esterase; HA, hemagglutinin; HEF, hemagglutinin-esterase fusion protein; NA, neuraminidase.
to reduce or enhance the binding of specific viruses [42] and affects SIA density as addition of 3- and 6-O-linked sulfate is in competition with α2,3 and α2,6 sialylation at terminal Gal residues. Fucosylation is another abundant modification affecting specific virus binding affinity [43] and terminal SLeX and/or SLeA terminal glycotopes (containing fucose) are frequently

Figure 2. Mucins and their glycosylation. (A) The domain structure of the soluble mucins MUC5B (5762 amino acids) and MUC5AC (5654 amino acids). The N- and C-terminal von Willebrand factor (vWF)-like regions and cysteine-rich domains are highly conserved between MUC5B and MUC5AC as well as between species. The four central proline/threonine/serine-rich (PTS) regions consist of imperfect repeats (aa; amino acids). PTS repeats are densely decorated with O-linked glycans and their low sequence conservation between species will result in spatial differences in glycan presentation that could potentially affect the binding of a specific virus. (B) Diversity of sialylated O-linked glycan structures present on high-molecular-weight human mucins. Structures were interpreted from the glycan compositions reported in the most extensive analysis of glycans on mucus to date [39]. Note that di-sialylated bi-antennary structures with multiple LacNAc repeats are present. Such structures on mucins are likely to have differential effects on the binding of viruses as has been reported for N-linked glycans [77]. Sulfation of the sialoglycans shown here was also abundant [39] but is not indicated. Abbreviations: Gal, galactose; GalNAc, N-acetylgalactosamine; GlcNAc, N-acetylglucosamine; Neu5Ac, N-acetyl-neuraminic acid.
found on O-linked glycans of human mucus and N-glycans of respiratory epithelium. Glycotopes, like the Sda antigen [blocking influenza A virus (IAV) binding to α2,3SIA [35]] and α2,6SIALacdiNAc, are abundant in ferrets whereas the terminal α-Gal epitope (Galα1,3Galβ1,4GlcNAc) that cannot be sialylated is abundant in swine, ferrets, and avian species. Other glycotopes concern modifications of the SIA itself such as Neu5Gc and O-acetylation at the C-4, -7, -8, and/or -9 positions. O-acetylation of SIA is known to vary considerably between species [6,44] and to affect virus binding to sialoglycans [4,10,11]. Viruses may also display preference for Neu5Ac or Neu5Gc [45]. Loss of function of CMAH, responsible for the production of Neu5Gc, occurred at least eight times in mammals – in humans and mustelids among others (but not in swine) – while also an entire avian lineage lacks Neu5Gc [46–48]. The absence or presence of glycotopes mentioned above, including SIA modifications, are likely to affect the zoonotic potential of SIA-binding viruses.

Respiratory mucus penetration by glycan-binding viruses

The mobility of viruses interacting with glycans is likely to be affected by heavily glycosylated mucus in a host species-specific manner. For viruses lacking RDE activity (Table 1) it is not well studied how they prevent being immobilized in the mucus layer. These viruses may bind at very low affinity and/or with very high specificity, thereby preventing high-avidity binding to glycans abundantly present in mucus. Viruses displaying RDE activity (Table 1), such as IAV, have been shown to require this activity to avoid immobilization in mucus [49–51]. These also include members of Orthomyxoviridae, Paramyxoviridae and Coronaviridae. Influenza A and B viruses and embecoviruses contain receptor-binding (hemagglutinin (HA) and spike (S)) and -cleaving (neuraminidase (NA) and hemagglutinin-esterase (HE)) functions in separate proteins. These activities are combined in a single protein for influenza C and D viruses and several paramyxoviruses [hemagglutinin-esterase fusion (HEF) and hemagglutinin-neuraminidase (HN) proteins]. Influenza A and B viruses and some paramyxoviruses prefer binding to either α2,3- or α2,6-linked SIAs, while embecoviruses, influenza C and D viruses bind to specifically O-acetylated SIAs (Table 1).

In view of the differences observed and anticipated between the sialoglycan repertoires of different host species, glycan-binding and -cleaving viruses likely need to adapt their sialoglycan interactions to successfully breach the host species barrier. Upon zoonotic transfer, animal IAVs not only adapt HA receptor binding (e.g., for avian viruses by switching receptor preference from α2,3- to α2,6-linked SIAs, the latter of which are abundantly present at the surface of epithelial cells in the upper respiratory tract of humans and swine) but also their NA-cleaving properties (reviewed in [7,52]). These latter adaptations may include changes that affect NA catalytic activity directly or indirectly, the latter for example by loss of a functional second SIA binding site, which is observed in all human viruses [53]. NA activity can also be adjusted by modification of the stalk length as frequently observed when viruses of wild waterfowl adapt to poultry [54]. Likewise, bovine coronaviruses that jumped into humans to become the novel human coronaviruses OC43 and HKU1 also reset their binding–cleaving balance to adapt to the human repertoire and/or densities of O-acetylated sialoglycans [11]. Analogous to the loss of a functional second SIA binding site in IAV NA, CoV-OC43 and -HKU1 lost the lectin function in HE as an adaptation to humans. Essentially nothing is known about the importance of balanced receptor-binding and -cleaving for the host range of paramyxoviruses.

For IAVs, the importance of well-balanced receptor-binding and -cleaving activity in enabling virus motility within respiratory mucus is demonstrated by several studies [49–51]. Inhibition of NA activity decreased IAV infection of mucus-secreting human tracheobronchial epithelial cultures [55] and increased inhibition by mucus in other IAV infection assays [51]. NA activity was furthermore shown to drive mobility of IAV particles in/on mucus [49,50]. The extent to which N-glycan-rich
exosomes [26] contribute to the inhibitory effect of mucus deserves greater attention. IAV binds, permanently but dynamically, via HA to receptor-coated surfaces, resulting in directional rolling-type motility that depends on NA activity [50,56,57]. Such motility has also been proposed for influenza C viruses [58] and coronaviruses [11,59,60], and the model can probably be extended to other viruses containing receptor-binding and -cleaving activities. We hypothesize that extended MUC5AC and MUC5B polymers provide a glycan track towards the epithelial cell surface for such motility [61]. The inhibition or support of virus transport by a mucus layer is fully dependent on the balance of receptor-binding and -destroying activity of a particular virus and on the mucus layer of a specific host. As such, the host- and organ-specific mucus glycome may facilitate infection by viruses that have coevolved with, and adapted to, their host for many years. Clearly, mucus can also function as an important barrier for zoonotic transfer that can only be overcome by much more rapid adaptations restoring the balance.

A comparison of inhibition of IAVs by mucus from different host species is mostly lacking. Human mucus was shown to inhibit swine and human viruses much more than swine mucus [62], which may be related to increased content of Neu5Gc and αGal epitope-containing glycans, at the expense

Table 2. Terminal glycotopes in the respiratory tract

| Glycotope | Structure | Mucus | Respiratory tract | Absent/ N.D./trace |
|-----------|-----------|-------|-------------------|-------------------|
| sLe^a     | β1,4 α 2,3 | Human [39] | Human [38] Avian [37] | Swine (N.D.) Ferret (N.D.) Horse (N.D.) Avian (N.D.) |
| Sda-epitope | β1,4 | Ferret [35] | Ferret [35] | Human (trace) Swine (N.D.) Ferret (N.D.) Avian (N.D.) |
| NeuGc     | β1,3/4 α 2,3/6 | Cow [4] | Swine [34,36] | Human Avian Ferret (N.D.) |
| αGal-epitope | β1,4 α 1,3 | Swine [33,34,36] Ferret [35] Avian [75] | Human |
| Neu5Ac-O-Ac (4/7/8/9-O) | β1,3/4 α 2,3/6 | Human (9-O) [4] Horse (4-0/7-0/8-0/9-0/7,9) | Cow (7-0/8-0/9-0/7,9-O) |
| Neu5Gc-O-Ac (1/8-O) | β1,3/4 α 2,3/6 | Swine (8-O) [4] Cow (7-O/8-O) |
| 2,6SIA-LactNAc | β1,4 α 2,6 | Ferret [35] | Human (N.D.) Swine (N.D.) |
| Sulfation (3S, 6S) | α Gal | Human [39] |

*Terminal structures at the non-reducing end of O- and N-linked glycan chains detected by mass spectrometry on epithelial cells or respiratory mucus in the indicated species. Differential expression at different locations along the respiratory tract has been analyzed in some cases but is not shown here. Neu5Ac (purple diamond), Neu5Gc (light blue diamond), N-acetylglucosamine (blue square), N-acetylgalactosamine (yellow square), galactose (yellow sphere), fucose (red triangle). S indicates sulfation.

Species in which a structure was not detectable (N.D.) or hardly detectable (trace) in extensive studies are indicated.
of Neu5Ac-containing functional epitopes. The inhibitory potential of bovine submaxillary mucin was affected by the removal of O-acetyl groups from SIAs in an IAV subtype-specific manner [4], which demonstrates the importance of host-specific glycosylation of mucus for its inhibitory potential. Viruses that breach the host species barrier presumable evolve towards variants with decreased affinity for abundant mucin decoy sialoglycans as was similarly observed previously for acquiring serum resistance of IAIs. For example, swine-serum-resistant variants displayed a markedly decreased affinity for total swine serum sialglycoproteins, while equine-serum-resistant viruses lost the ability to bind the NA-resistant 4-O-acetylated SIA moieties of equine c2-macroglobulin [63]. Similar studies on this topic using mucus from different species are absent thus far.

Concluding remarks
While there is ample evidence for the protective function of mucus against glycan-binding viruses, there is no evidence for the protective function of mucus against glycan-binding viruses, as well as for the countering function of viral RDEs, relatively little is still known on the species-specific properties of mucus against the establishment of zoonotic and enzootic infections. Numerous observations discussed in this paper are, however, indicative for such a function. With the advent of more sensitive and quantitative glycomic methods, as well as increasing knowledge and expanding techniques for the analysis of virus–receptor interaction dynamics and specificity, rapid progress on this issue can in principle be made. See Outstanding questions for the most urgent open questions. The principal importance of such studies lays in the acquisition of a better assessment of the zoonotic threats posed by animal viruses.

Declarations of interests
There are no interests to declare.

References
1. Lienho, E.P. et al. (2013) Cellular and molecular biology of airway mucins. Int. Rev. Cell Mol. Biol. 303, 139–202
2. Zanin, M. et al. (2016) The interaction between respiratory pathogens and mucus. Curr. Host Microbe 19, 159–168
3. Matrosovich, M. et al. (2018) Sialic acid receptors of viruses. In Sialic Glycochemistry and Biology II: Tools and Techniques to Identify and Capture Sialoglycans (Gerardy-Schild, R. et al., eds), pp. 1–29, Springer International Publishing
4. Bannard, K.N. et al. (2020) Modified sialic acids on mucus and erythrocytes inhibit influenza A virus hemagglutinin and neuraminidase functions. J. Virol. 94, e01567–19
5. Varki, A. et al. (2017) Sialic acids and other nonulosonic acids. In Essentials of Glycobiology (Varki, A. et al., eds), Cold Spring Harbor Laboratory Press
6. Langereis, M.A. et al. (2015) Complexity and diversity of the mammalian salome revealed by nidovirus virolectins. Curr. Rep. 11, 1966–1978
7. de Graaf, M. and Fouchier, R.A. (2014) Role of receptor binding specificity in influenza A virus transmission and pathogenesis. EMBO J. 33, 823–841
8. Bylund-Leo las, L. et al. (2017) The interplay between the host receptor and influenza virus hemagglutinin and neuraminidase. Int. J. Mol. Sci. 18, 1541
9. Wagner, R. et al. (2002) Functional balance between haemagglutinin and neuraminidase in influenza virus infections. Rev. Med. Virol. 12, 159–166
10. Waski, B.R. et al. (2016) Effects of sialic acid modifications on virus binding and infection. Trends Microbiol. 24, 901–1001
11. Lang, Y. et al. (2020) Coronavirus hemagglutinin–esterase and spike proteins cooperate for functional balance and optimal virion avidity. Proc. Natl Acad. Sci. U. S. A. 117, 25759–25770
12. Futter, B. et al. (2012) A periciliary brush promotes the lung health by separating the mucus layer from airway epithelia. Science 337, 957–961
13. Witten, J. et al. (2018) Selective permeability of mucus barriers. Curr. Opin. Biotechnol. 52, 124–133
14. Fahy, J.V. and Dickey, B.F. (2010) Airway mucus function and dysfunction. N. Engl. J. Med. 363, 2203–2247
15. Tomasic, P.V. et al. (2020) Nasal mucus proteome and its involvement in allergic rhinitis. Exp. Rev. Proteom. 17, 191–199
16. Atanasova, K.R. and Reznikov, L.R. (2019) Strategies for measuring airway mucus and mucus. Respir. Rev. 20, 261
17. Joo, N.S. et al. (2019) Proteinomic analysis of pure human airway gland mucus reveals a large component of protective proteins. PLoS One 10, e0116756
18. Park, M.S. et al. (2018) Towards the application of human defensins as antivirals. Biomol. Ther. (Seoul) 26, 242–254
19. Weiske, S. et al. (2013) Lactoferrin for prevention of common viral infections. J. Infect. Chemother. 20, 666–671
20. Akrum, K.M. et al. (2018) An innate defense peptide BPIFA1/SPLUNC1 restricts influenza A virus infection. Mucosal Immunol. 11, 71–81
21. Tripathi, S. et al. (2013) The human cathelicidin LL-37 inhibits influenza A viruses through a mechanism distinct from that of surfactant protein D or defensins. J. Gen. Virol. 94, 40–49
22. Levine, A.M. et al. (2001) Surfactant protein D enhances clearance of influenza A virus from the lung in vivo. J. Virol. 75, 5322–5332
23. Ligtenberg, A.J. et al. (2010) Deleted in malignant brain tumors-1 protein (DMBT1): a pattern recognition receptor with multiple binding sites. Int. J. Mol. Sci. 11, 5232–5233
24. Yang, M.L. et al. (2011) Galectin-1 binds to influenza virus and ameliorates influenza virus pathogenesis. J. Virol. 85, 10010–10019
25. Bedford, J.G. et al. (2000) Airway exosomes released during influenza virus infection serve as a key component of the antiviral innate immune response. Front. Immunol. 11, 887
26. Keasler, M. et al. (2009) Characterization of exosome-like vesicles released from human tracheobronchial ciliated epithelium: a possible role in innate defense. FASEB J. 23, 1856–1868
27. Bartlett, J.A. et al. (2013) Protein composition of bronchoalveolar lavage fluid and airway surface liquid from newborn pigs. Am. J. Physiol. Lung Cell Mol. Physiol. 305, L256–L266
28. Guo, Y. et al. (2009) 1-DE MS and 2-D LC-MS analysis of the mouse bronchoalveolar lavage proteome. Proteomics 9, 4608–4624

Outstanding questions
To what extent does the mucus glycome differ between species? Detailed glycomic analysis of the mucins of species other than human is urgently required. Information on the SIA linkage type (especially on LacNAc repeats present on O- and N-linked glycans) is highly relevant. The proteome and glycome of the globular proteins is largely unknown for any species. Virus-binding studies to the identified glycans, as well as to mucins and soluble proteins, should complement these studies.

How does virus motility in a mucous layer depend on the balance between mucus glycan receptors and viral RBP and RDE activity? To quantify this balance, the binding affinity/avidity and RDE activity/specificity of viruses with mucus of different species needs to be determined and correlated to the corresponding glycome as well as to motility and the dynamics of the interaction between viruses and mucin networks.

Is there a host-specific RBP/RDE receptor balance to which viruses have to adapt to become established in a novel host species? In other words, can we prove that the mucus layer is a major zoonotic barrier? Adaptation of a virus to the functional cell-surface receptors in a novel host has been described in detail for influenza and coronaviruses. However, the extent to which adaptation to decoy receptors in the mucus layer, if at all, has taken place, and has then always been a requirement for establishment in another species, has hardly been described.

How do glycan-binding viruses that lack a RDE prevent immobilization in the mucus? Few data are available on the motility of such viruses in a mucus layer. It is expected that motility is mainly dependent on a receptor/RBP balance and therefore on the kinetic binding parameters (Kp, Ka of mono-molecular interactions) and binding polymerality of such viruses. Whether there is any directionality in their movement is unknown.

What is the role of mucins in the formation and egress of infectious particles? Little is known about the role of mucins in respiratory virus
29. Häggblom, S. et al. (2017) Proteome analysis of bronchoalveolar lavage from calves infected with bovine respiratory syncytial virus: Insights in pathogenesis and perspectives for new treatments. PLoS One 12, e0186594
30. Leak, J. et al. (2017) Physicochemical properties of mucus and their impact on transmucosal drug delivery. Int. J. Pharm. 535, 555–572
31. Yang, X. et al. (2012) Immobilization of pseudoviruses in porcine tracheal respiratory mucus revealed by single particle tracking. PLoS One 7, e51054
32. Ramachandran, P. et al. (2008) Identification of N-linked glycoproteins in human saliva by glycoprotein capture and mass spectrometry. J. Proteome Res. 7, 1495–1503
33. Bateman, A.C. et al. (2010) Glycan analysis and influenza A virus infection of primary swine respiratory epithelial cells: the importance of NeuAc(alpha2-6) glycans. J. Biol. Chem. 285, 34016–34026
34. Chen, R.W. et al. (2013) Infection of sputum and sputum virus with mucus including H7N9 and correlation with glycamic analysis. Influenza Other Respir. Viruses 7, 1269–1282
35. Jia, N. et al. (2014) Glycomic characterization of respiratory tract tissue samples for infection and virus infection studies. J. Biol. Chem. 289, 28489–28504
36. Sriwilaijaroen, N. et al. (2011) N-glycans from porcine tracheae and lung: predominant NeuAc(alpha2-3) glycan could be a selective pressure for influenza variants in favor of human-type receptor. PLoS One 6, e16302
37. Hiono, T. et al. (2014) A chicken influenza virus recognizes fucosylated G2,3 sialoylgalactose receptors on the epithelial cells lining upper respiratory tracts of chickens. Virusology 456–457, 131–138
38. Morelle, W. et al. (2001) FAB-MS characterization of sialic Lewis x determinants on polyolactosamine chains of human airway mucins secreted by patients suffering from cystic fibrosis or chronic bronchitis. Glycobiology. 11, 699–708
39. Xia, B. et al. (2005) Altered O-glycosylation and sulfation of airway mucus associated with cystic fibrosis. Glycobiology 15, 747–775
40. Hino, M. et al. (2011) Lectin-based structural glycomics: a practical approach to complex glyans. Electrophoresis 32, 1118–1129
41. Hansich, F.G. (2001) O-glycosylation of the mucin type. Biol. Chem. 382, 143–149
42. Gambaryan, A.S. et al. (2018) Receptor-binding properties of influenza viruses isolated from guilis. Virology 522, 37–45
43. Guo, H. et al. (2017) Highly pathogenic influenza A(H5N1) viruses with altered H5 receptor-binding specificity. Emerg. Infect. Dis. 23, 220–231
44. Wasik, B.R. et al. (2017) Distribution of O-acetylated steric acids among target-host tissues for influenza virus, m2H5, e0079-16
45. Broszetz, F. et al. (2019) N-glycolylneuraminic acid as a receptor for avian influenza A viruses. Cell Rep. 27, 13294–13294
46. Springston, S.A. et al. (2014) Parallel evolution of a self-host: humans and new world monkeys independently lost the cell surface sugar NeuGc. Immune. 66, 671–674
47. Ng, P.S. et al. (2016) Ferrets exclusively synthesize Neu5Ac and express naturally humanized influenza A virus receptors. Nat. Commun. 5, 5750
48. Pet, S. et al. (2018) Phylogenetic distribution of OMP-Neu5Ac hydroxide (CM4y), the enzyme synthesizing the proinflammatory human-synthetic Neu5Gc. Genome Biol. 19, 207–219
49. Yang, X. et al. (2014) A beneficiary role for neuraminidase in influenza virus penetration through the respiratory mucus. PLoS One 9, e108266
50. Vaheri, M.D. and Pethcer, D.A. (2019) Influenza A virus surface proteins are organized to help penetrate host mucus. eLife, e63764
51. Cohen, M. et al. (2013) Influenza A neuraminidase hosts mucus through cell-surface proteins with neuraminidase. Viral J. 10, 321
52. Gambaryan, A.S. and Matsurovich, M.N. (2015) What adaptive changes in hemagglutinin and neuraminidase are necessary for emergence of pandemic influenza virus from its avian precursor? Biochemistry 54, 80, 572–580
53. Du, W. et al. (2020) Second sialic acid-binding site of influenza A virus neuraminidase: binding receptors for efficient release. FEBS J.